{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:06:41Z","timestamp":1792710401052,"version":"4.5.0"},"reference-count":113,"publisher":"Innovative Healthcare Institute","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Cancer manifestation is a multistep process involving accumulation of various genetic and epigenetic changes that results in oncogenic \u201challmarks of cancer\u201d processes including genomic instability. Exploitation of aberrant DNA-damage response (DDR) mechanisms in cancer is in part a goal of many therapeutic strategies, and recent evidence supports the role of targeting DDR in modulating the tumor immune microenvironment to enhance immunotherapeutic response. Improved cancer profiling, including next-generation and whole-genome mutational sequencing of tumor tissue, as well as circulating nucleic acids, has enhanced our understanding of the genetic and epigenetic molecular mechanisms in tumorigenesis and will become fundamental to precisely target tumors and achieve cancer control. With the successes of poly(ADP-ribose) polymerase inhibitors (PARPi) and immunotherapies, the intersection of DDR molecular machinery and corresponding antitumor immune response has gained much interest with a focus on achieving therapeutic synergy using DNA damage-targeting agents and immunotherapy. In this review, we provide a bench-to-bedside overview of the fundamentals of DDR signaling and repair as they relate to cancer therapeutic strategies including novel DDR-targeting agents. We also discuss the underlying mechanisms that link DDR signaling to antitumor immunity and immunotherapy efficacy, and how this knowledge can be used to improve precision medicine approaches in the treatment of cancer.<\/jats:p>","DOI":"10.36401\/jipo-22-15","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:47:45Z","timestamp":1669974465000},"page":"31-49","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors"],"prefix":"10.36401","volume":"6","author":[{"given":"Curtis A.","family":"Clark","sequence":"first","affiliation":[{"name":"1 Department of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy S.","family":"Yang","sequence":"additional","affiliation":[{"name":"1 Department of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA"},{"name":"2 O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA"},{"name":"3 Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"2023013016571672700_i2590-017X-6-1-31-b01","doi-asserted-by":"crossref","unstructured":"Lord\n              CJ,\n            \n            \n              Ashworth\n              A.\n            \n          \n          The DNA damage response and cancer therapy.\n\t\t\t\t\tNature.\n\t\t\t\t\t2012;\n\t\t\t\t\t481:\n\t\t\t\t\t287\u2013\n\t\t\t\t\t294.","DOI":"10.1038\/nature10760"},{"key":"2023013016571672700_i2590-017X-6-1-31-b02","doi-asserted-by":"crossref","unstructured":"Burrell\n              RA,\n            \n            \n              McGranahan\n              N,\n            \n            \n              Bartek\n              J,\n            \n            \n              Swanton\n              C.\n            \n          \n          The causes and consequences of genetic heterogeneity in cancer evolution.\n\t\t\t\t\tNature.\n\t\t\t\t\t2013;\n\t\t\t\t\t501:\n\t\t\t\t\t338\u2013\n\t\t\t\t\t345.","DOI":"10.1038\/nature12625"},{"key":"2023013016571672700_i2590-017X-6-1-31-b03","doi-asserted-by":"crossref","unstructured":"Klinakis\n              A,\n            \n            \n              Karagiannis\n              D,\n            \n            \n              Rampias\n              T.\n            \n          \n          Targeting DNA repair in cancer: current state and novel approaches.\n\t\t\t\t\tCell Mol Life Sci.\n\t\t\t\t\t2020;\n\t\t\t\t\t77:\n\t\t\t\t\t677\u2013\n\t\t\t\t\t703.","DOI":"10.1007\/s00018-019-03299-8"},{"key":"2023013016571672700_i2590-017X-6-1-31-b04","doi-asserted-by":"crossref","unstructured":"Lord\n              CJ,\n            \n            \n              Ashworth\n              A.\n            \n          \n          PARP inhibitors: synthetic lethality in the clinic.\n\t\t\t\t\tScience.\n\t\t\t\t\t2017;\n\t\t\t\t\t355:\n\t\t\t\t\t1152\u2013\n\t\t\t\t\t1158.","DOI":"10.1126\/science.aam7344"},{"key":"2023013016571672700_i2590-017X-6-1-31-b05","doi-asserted-by":"crossref","unstructured":"Tung\n              NM,\n            \n            \n              Robson\n              ME,\n            \n            \n              Ventz\n              S,\n            \n            et al.\n          \n          TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t38(36):\n\t\t\t\t\t4274\u2013\n\t\t\t\t\t4282.","DOI":"10.1200\/JCO.20.02151"},{"key":"2023013016571672700_i2590-017X-6-1-31-b06","doi-asserted-by":"crossref","unstructured":"Ashworth\n              A.\n            \n          \n          A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2008;\n\t\t\t\t\t26:\n\t\t\t\t\t3785\u2013\n\t\t\t\t\t3790.","DOI":"10.1200\/JCO.2008.16.0812"},{"key":"2023013016571672700_i2590-017X-6-1-31-b07","doi-asserted-by":"crossref","unstructured":"Sato\n              H,\n            \n            \n              Niimi\n              A,\n            \n            \n              Yasuhara\n              T,\n            \n            et al.\n          \n          DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2017;\n\t\t\t\t\t8:\n\t\t\t\t\t1751.","DOI":"10.1038\/s41467-017-01883-9"},{"key":"2023013016571672700_i2590-017X-6-1-31-b08","doi-asserted-by":"crossref","unstructured":"Samstein\n              RM,\n            \n            \n              Lee\n              CH,\n            \n            \n              Shoushtari\n              AN,\n            \n            et al.\n          \n          Tumor mutational load predicts survival after immunotherapy across multiple cancer types.\n\t\t\t\t\tNat Genet.\n\t\t\t\t\t2019;\n\t\t\t\t\t51:\n\t\t\t\t\t202\u2013\n\t\t\t\t\t206.","DOI":"10.1038\/s41588-018-0312-8"},{"key":"2023013016571672700_i2590-017X-6-1-31-b09","doi-asserted-by":"crossref","unstructured":"Yarchoan\n              M,\n            \n            \n              Hopkins\n              A,\n            \n            \n              Jaffee\n              EM.\n            \n          \n          Tumor mutational burden and response rate to PD-1 inhibition.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t377:\n\t\t\t\t\t2500\u2013\n\t\t\t\t\t2501.","DOI":"10.1056\/NEJMc1713444"},{"key":"2023013016571672700_i2590-017X-6-1-31-b10","doi-asserted-by":"crossref","unstructured":"Ablasser\n              A,\n            \n            \n              Goldeck\n              M,\n            \n            \n              Cavlar\n              T,\n            \n            et al.\n          \n          cGAS produces a 2\u2032-5\u2032-linked cyclic dinucleotide second messenger that activates STING.\n\t\t\t\t\tNature.\n\t\t\t\t\t2013;\n\t\t\t\t\t498:\n\t\t\t\t\t380\u2013\n\t\t\t\t\t384.","DOI":"10.1038\/nature12306"},{"key":"2023013016571672700_i2590-017X-6-1-31-b11","doi-asserted-by":"crossref","unstructured":"Ribas\n              A,\n            \n            \n              Wolchok\n              JD.\n            \n          \n          Cancer immunotherapy using checkpoint blockade.\n\t\t\t\t\tScience.\n\t\t\t\t\t2018;\n\t\t\t\t\t359:\n\t\t\t\t\t1350\u2013\n\t\t\t\t\t1355.","DOI":"10.1126\/science.aar4060"},{"key":"2023013016571672700_i2590-017X-6-1-31-b12","doi-asserted-by":"crossref","unstructured":"Strickland\n              KC,\n            \n            \n              Howitt\n              BE,\n            \n            \n              Shukla\n              SA,\n            \n            et al.\n          \n          Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer.\n\t\t\t\t\tOncotarget.\n\t\t\t\t\t2016;\n\t\t\t\t\t7:\n\t\t\t\t\t13587\u2013\n\t\t\t\t\t13598.","DOI":"10.18632\/oncotarget.7277"},{"key":"2023013016571672700_i2590-017X-6-1-31-b13","doi-asserted-by":"crossref","unstructured":"Heijink\n              AM,\n            \n            \n              Talens\n              F,\n            \n            \n              Jae\n              LT,\n            \n            et al.\n          \n          BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t100.","DOI":"10.1038\/s41467-018-07927-y"},{"key":"2023013016571672700_i2590-017X-6-1-31-b14","doi-asserted-by":"crossref","unstructured":"Sen\n              T,\n            \n            \n              Rodriguez\n              BL,\n            \n            \n              Chen\n              L,\n            \n            et al.\n          \n          Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2019;\n\t\t\t\t\t9:\n\t\t\t\t\t646\u2013\n\t\t\t\t\t661.","DOI":"10.1158\/2159-8290.CD-18-1020"},{"key":"2023013016571672700_i2590-017X-6-1-31-b15","doi-asserted-by":"crossref","unstructured":"Fridman\n              WH,\n            \n            \n              Zitvogel\n              L,\n            \n            \n              Saute\u0300s\u2013Fridman\n              C,\n            \n            \n              Kroemer\n              G.\n            \n          \n          The immune contexture in cancer prognosis and treatment.\n\t\t\t\t\tNat Rev Clin Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t14:\n\t\t\t\t\t717\u2013\n\t\t\t\t\t734.","DOI":"10.1038\/nrclinonc.2017.101"},{"key":"2023013016571672700_i2590-017X-6-1-31-b16","doi-asserted-by":"crossref","unstructured":"Nolan\n              E,\n            \n            \n              Savas\n              P,\n            \n            \n              Policheni\n              AN,\n            \n            et al.\n          \n          Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.\n\t\t\t\t\tSci Transl Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t9:\n\t\t\t\t\t4922.","DOI":"10.1126\/scitranslmed.aal4922"},{"key":"2023013016571672700_i2590-017X-6-1-31-b17","doi-asserted-by":"crossref","unstructured":"Hanahan\n              D.\n            \n          \n          Hallmarks of cancer: new dimensions.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2022;\n\t\t\t\t\t12:\n\t\t\t\t\t31\u2013\n\t\t\t\t\t46.","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"2023013016571672700_i2590-017X-6-1-31-b18","doi-asserted-by":"crossref","unstructured":"Lamberti\n              G,\n            \n            \n              Andrini\n              E,\n            \n            \n              Sisi\n              M,\n            \n            et al.\n          \n          Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.\n\t\t\t\t\tFuture Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t16:\n\t\t\t\t\t1751\u2013\n\t\t\t\t\t1766.","DOI":"10.2217\/fon-2020-0215"},{"key":"2023013016571672700_i2590-017X-6-1-31-b19","doi-asserted-by":"crossref","unstructured":"Brown\n              JS,\n            \n            \n              O'Carrigan\n              B,\n            \n            \n              Jackson\n              SP,\n            \n            \n              Yap\n              TA.\n            \n          \n          Targeting DNA repair in cancer: beyond PARP inhibitors.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2017;\n\t\t\t\t\t7:\n\t\t\t\t\t20\u2013\n\t\t\t\t\t37.","DOI":"10.1158\/2159-8290.CD-16-0860"},{"key":"2023013016571672700_i2590-017X-6-1-31-b20","doi-asserted-by":"crossref","unstructured":"Blackford\n              AN,\n            \n            \n              Jackson\n              SP. ATM,\n            \n          \n          ATR, and DNA-PK: the trinity at the heart of the DNA damage response.\n\t\t\t\t\tMol Cell.\n\t\t\t\t\t2017;\n\t\t\t\t\t66:\n\t\t\t\t\t801\u2013\n\t\t\t\t\t817.","DOI":"10.1016\/j.molcel.2017.05.015"},{"key":"2023013016571672700_i2590-017X-6-1-31-b21","doi-asserted-by":"crossref","unstructured":"Tubbs\n              A,\n            \n            \n              Nussenzweig\n              A.\n            \n          \n          Endogenous DNA damage as a source of genomic instability in cancer.\n\t\t\t\t\tCell.\n\t\t\t\t\t2017;\n\t\t\t\t\t168:\n\t\t\t\t\t644\u2013\n\t\t\t\t\t656.","DOI":"10.1016\/j.cell.2017.01.002"},{"key":"2023013016571672700_i2590-017X-6-1-31-b22","doi-asserted-by":"crossref","unstructured":"Robinson\n              D,\n            \n            \n              Van Allen\n              EM,\n            \n            \n              Wu\n              YM,\n            \n            et al.\n          \n          Integrative clinical genomics of advanced prostate cancer.\n\t\t\t\t\tCell.\n\t\t\t\t\t2015;\n\t\t\t\t\t161:\n\t\t\t\t\t1215\u2013\n\t\t\t\t\t1228.","DOI":"10.1016\/j.cell.2015.05.001"},{"key":"2023013016571672700_i2590-017X-6-1-31-b23","doi-asserted-by":"crossref","unstructured":"Ellisen\n              LW.\n            \n          \n          PARP inhibitors in cancer therapy: promise, progress, and puzzles.\n\t\t\t\t\tCancer Cell.\n\t\t\t\t\t2011;\n\t\t\t\t\t19:\n\t\t\t\t\t165\u2013\n\t\t\t\t\t167.","DOI":"10.1016\/j.ccr.2011.01.047"},{"key":"2023013016571672700_i2590-017X-6-1-31-b24","doi-asserted-by":"crossref","unstructured":"Pilie\n              PG,\n            \n            \n              Tang\n              C,\n            \n            \n              Mills\n              GB,\n            \n            \n              Yap\n              TA.\n            \n          \n          State-of-the-art strategies for targeting the DNA damage response in cancer.\n\t\t\t\t\tNat Rev Clin Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t16:\n\t\t\t\t\t81\u2013\n\t\t\t\t\t104.","DOI":"10.1038\/s41571-018-0114-z"},{"key":"2023013016571672700_i2590-017X-6-1-31-b25","doi-asserted-by":"crossref","unstructured":"O'Connor\n              MJ.\n            \n          \n          Targeting the DNA damage response in cancer.\n\t\t\t\t\tMol Cell.\n\t\t\t\t\t2015;\n\t\t\t\t\t60:\n\t\t\t\t\t547\u2013\n\t\t\t\t\t560.","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"2023013016571672700_i2590-017X-6-1-31-b26","doi-asserted-by":"crossref","unstructured":"Farmer\n              H,\n            \n            \n              McCabe\n              N,\n            \n            \n              Lord\n              CJ,\n            \n            et al.\n          \n          Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.\n\t\t\t\t\tNature.\n\t\t\t\t\t2005;\n\t\t\t\t\t434:\n\t\t\t\t\t917\u2013\n\t\t\t\t\t921.","DOI":"10.1038\/nature03445"},{"key":"2023013016571672700_i2590-017X-6-1-31-b27","doi-asserted-by":"crossref","unstructured":"Golan\n              T,\n            \n            \n              Hammel\n              P,\n            \n            \n              Reni\n              M,\n            \n            et al.\n          \n          Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t381:\n\t\t\t\t\t317\u2013\n\t\t\t\t\t327.","DOI":"10.1056\/NEJMoa1903387"},{"key":"2023013016571672700_i2590-017X-6-1-31-b28","doi-asserted-by":"crossref","unstructured":"Litton\n              JK,\n            \n            \n              Rugo\n              HS,\n            \n            \n              Ettl\n              J,\n            \n            et al.\n          \n          Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t379:\n\t\t\t\t\t753\u2013\n\t\t\t\t\t763.","DOI":"10.1056\/NEJMoa1802905"},{"key":"2023013016571672700_i2590-017X-6-1-31-b29","doi-asserted-by":"crossref","unstructured":"Robson\n              M,\n            \n            \n              Im\n              SA,\n            \n            \n              Senkus\n              E,\n            \n            et al.\n          \n          Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation. Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t377:\n\t\t\t\t\t523\u2013\n\t\t\t\t\t533.","DOI":"10.1056\/NEJMoa1706450"},{"key":"2023013016571672700_i2590-017X-6-1-31-b30","doi-asserted-by":"crossref","unstructured":"Litton\n              JK,\n            \n            \n              Hurvitz\n              SA,\n            \n            \n              Mina\n              LA,\n            \n            et al.\n          \n          Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t31:\n\t\t\t\t\t1526\u2013\n\t\t\t\t\t1535.","DOI":"10.1016\/j.annonc.2020.08.2098"},{"key":"2023013016571672700_i2590-017X-6-1-31-b31","doi-asserted-by":"crossref","unstructured":"Nowsheen\n              S,\n            \n            \n              Cooper\n              T,\n            \n            \n              Stanley\n              JA,\n            \n            \n              Yang\n              ES.\n            \n          \n          Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2012;\n\t\t\t\t\t7:\n\t\t\t\t\te46614.","DOI":"10.1371\/journal.pone.0046614"},{"key":"2023013016571672700_i2590-017X-6-1-31-b32","doi-asserted-by":"crossref","unstructured":"Verma\n              N,\n            \n            \n              Vinik\n              Y,\n            \n            \n              Saroha\n              A,\n            \n            et al.\n          \n          Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis.\n\t\t\t\t\tSci Adv.\n\t\t\t\t\t2020;\n\t\t\t\t\t6:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t18.","DOI":"10.1126\/sciadv.aba8968"},{"key":"2023013016571672700_i2590-017X-6-1-31-b33","doi-asserted-by":"crossref","unstructured":"Li\n              Y,\n            \n            \n              Wang\n              Y,\n            \n            \n              Zhang\n              W,\n            \n            et al.\n          \n          BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.\n\t\t\t\t\tSci Rep.\n\t\t\t\t\t2021;\n\t\t\t\t\t11:\n\t\t\t\t\t4774.","DOI":"10.1038\/s41598-021-82990-y"},{"key":"2023013016571672700_i2590-017X-6-1-31-b34","doi-asserted-by":"crossref","unstructured":"Stringer-Reasor\n              EM,\n            \n            \n              May\n              JE,\n            \n            \n              Olariu\n              E,\n            \n            et al.\n          \n          An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.\n\t\t\t\t\tBreast Cancer Res.\n\t\t\t\t\t2021;\n\t\t\t\t\t23:\n\t\t\t\t\t30.","DOI":"10.1186\/s13058-021-01408-9"},{"key":"2023013016571672700_i2590-017X-6-1-31-b35","doi-asserted-by":"crossref","unstructured":"Oaknin\n              A,\n            \n            \n              Oza\n              AM,\n            \n            \n              Lorusso\n              D,\n            \n            et al.\n          \n          Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: the effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.\n\t\t\t\t\tCancer Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t10:\n\t\t\t\t\t7162\u2013\n\t\t\t\t\t7173.","DOI":"10.1002\/cam4.4260"},{"key":"2023013016571672700_i2590-017X-6-1-31-b36","doi-asserted-by":"crossref","unstructured":"Poveda\n              A,\n            \n            \n              Floquet\n              A,\n            \n            \n              Ledermann\n              JA,\n            \n            et al.\n          \n          Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2021;\n\t\t\t\t\t22:\n\t\t\t\t\t620\u2013\n\t\t\t\t\t631.","DOI":"10.1097\/OGX.0000000000000962"},{"key":"2023013016571672700_i2590-017X-6-1-31-b37","doi-asserted-by":"crossref","unstructured":"Swisher\n              EM,\n            \n            \n              Kwan\n              TT,\n            \n            \n              Oza\n              AM,\n            \n            et al.\n          \n          Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2021;\n\t\t\t\t\t12:\n\t\t\t\t\t2487.","DOI":"10.1038\/s41467-021-22582-6"},{"key":"2023013016571672700_i2590-017X-6-1-31-b38","doi-asserted-by":"crossref","unstructured":"Kaufman\n              B,\n            \n            \n              Shapira-Frommer\n              R,\n            \n            \n              Schmutzler\n              RK,\n            \n            et al.\n          \n          Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t33:\n\t\t\t\t\t244\u2013\n\t\t\t\t\t250.","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"2023013016571672700_i2590-017X-6-1-31-b39","doi-asserted-by":"crossref","unstructured":"Swisher\n              EM,\n            \n            \n              Lin\n              KK,\n            \n            \n              Oza\n              AM,\n            \n            et al.\n          \n          Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t18:\n\t\t\t\t\t75\u2013\n\t\t\t\t\t87.","DOI":"10.1016\/S1470-2045(16)30559-9"},{"key":"2023013016571672700_i2590-017X-6-1-31-b40","doi-asserted-by":"crossref","unstructured":"Kristeleit\n              R,\n            \n            \n              Lisyanskaya\n              A,\n            \n            \n              Fedenko\n              A,\n            \n            et al.\n          \n          Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2022;\n\t\t\t\t\t23:\n\t\t\t\t\t465\u2013\n\t\t\t\t\t478.","DOI":"10.1016\/S1470-2045(22)00122-X"},{"key":"2023013016571672700_i2590-017X-6-1-31-b41","doi-asserted-by":"crossref","unstructured":"Tutt\n              ANJ,\n            \n            \n              Garber\n              JE,\n            \n            \n              Kaufman\n              B,\n            \n            et al.\n          \n          Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t384:\n\t\t\t\t\t2394\u2013\n\t\t\t\t\t2405.","DOI":"10.1056\/NEJMoa2105215"},{"key":"2023013016571672700_i2590-017X-6-1-31-b42","doi-asserted-by":"crossref","unstructured":"Somlo\n              G,\n            \n            \n              Frankel\n              PH,\n            \n            \n              Arun\n              BK,\n            \n            et al.\n          \n          Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t23:\n\t\t\t\t\t4066\u2013\n\t\t\t\t\t4076.","DOI":"10.1158\/1078-0432.CCR-16-2714"},{"key":"2023013016571672700_i2590-017X-6-1-31-b43","doi-asserted-by":"crossref","unstructured":"Han\n              H,\n            \n            \n              Liu\n              MC,\n            \n            \n              Hamilton\n              E,\n            \n            et al.\n          \n          Abstract P3-11-03: Pilot neoadjuvant study of niraparib in HER2-negative, BRCA-mutated resectable breast cancer. Cancer Res.\n          2020;\n\t\t\t\t\t80(4_Supplement):P3-11-03.","DOI":"10.1158\/1538-7445.SABCS19-P3-11-03"},{"key":"2023013016571672700_i2590-017X-6-1-31-b44","doi-asserted-by":"crossref","unstructured":"Severson\n              TM,\n            \n            \n              Wolf\n              DM,\n            \n            \n              Yau\n              C,\n            \n            et al.\n          \n          The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.\n\t\t\t\t\tBreast Cancer Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t19:\n\t\t\t\t\t99.","DOI":"10.1186\/s13058-017-0861-2"},{"key":"2023013016571672700_i2590-017X-6-1-31-b45","doi-asserted-by":"crossref","unstructured":"Hussain\n              M,\n            \n            \n              Mateo\n              J,\n            \n            \n              Fizazi\n              K,\n            \n            et al.\n          \n          Survival with olaparib in metastatic castration-resistant prostate cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t383:\n\t\t\t\t\t2345\u2013\n\t\t\t\t\t2357.","DOI":"10.1056\/NEJMoa2022485"},{"key":"2023013016571672700_i2590-017X-6-1-31-b46","doi-asserted-by":"crossref","unstructured":"Carreira\n              S,\n            \n            \n              Porta\n              N,\n            \n            \n              Arce-Gallego\n              S,\n            \n            et al.\n          \n          Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B Trial.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2021;\n\t\t\t\t\t11:\n\t\t\t\t\t2812\u2013\n\t\t\t\t\t2827.","DOI":"10.1158\/2159-8290.CD-21-0007"},{"key":"2023013016571672700_i2590-017X-6-1-31-b47","doi-asserted-by":"crossref","unstructured":"Mateo\n              J,\n            \n            \n              Porta\n              N,\n            \n            \n              Bianchini\n              D,\n            \n            et al.\n          \n          Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t21:\n\t\t\t\t\t162\u2013\n\t\t\t\t\t174.","DOI":"10.1016\/S1470-2045(19)30684-9"},{"key":"2023013016571672700_i2590-017X-6-1-31-b48","doi-asserted-by":"crossref","unstructured":"Mateo\n              J,\n            \n            \n              Carreira\n              S,\n            \n            \n              Sandhu\n              S,\n            \n            et al.\n          \n          DNA-repair defects and olaparib in metastatic prostate cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2015;\n\t\t\t\t\t373:\n\t\t\t\t\t1697\u2013\n\t\t\t\t\t1708.","DOI":"10.1056\/NEJMoa1506859"},{"key":"2023013016571672700_i2590-017X-6-1-31-b49","doi-asserted-by":"crossref","unstructured":"Abida\n              W,\n            \n            \n              Patnaik\n              A,\n            \n            \n              Campbell\n              D,\n            \n            et al.\n          \n          Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t38:\n\t\t\t\t\t3763\u2013\n\t\t\t\t\t3772.","DOI":"10.1200\/JCO.20.01035"},{"key":"2023013016571672700_i2590-017X-6-1-31-b50","doi-asserted-by":"crossref","unstructured":"Loehr\n              A,\n            \n            \n              Patnaik\n              A,\n            \n            \n              Campbell\n              D,\n            \n            et al.\n          \n          Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 Study.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2021;\n\t\t\t\t\t27:\n\t\t\t\t\t6677\u2013\n\t\t\t\t\t6686.","DOI":"10.1158\/1078-0432.CCR-21-2199"},{"key":"2023013016571672700_i2590-017X-6-1-31-b51","doi-asserted-by":"crossref","unstructured":"Abida\n              W,\n            \n            \n              Campbell\n              D,\n            \n            \n              Patnaik\n              A,\n            \n            et al.\n          \n          Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the Phase II TRITON2 Study.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\t2487\u2013\n\t\t\t\t\t2496.","DOI":"10.1158\/1078-0432.CCR-20-0394"},{"key":"2023013016571672700_i2590-017X-6-1-31-b52","doi-asserted-by":"crossref","unstructured":"de Bono\n              JS,\n            \n            \n              Mehra\n              N,\n            \n            \n              Scagliotti\n              GV,\n            \n            et al.\n          \n          Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2021;\n\t\t\t\t\t22:\n\t\t\t\t\t1250\u2013\n\t\t\t\t\t1264.","DOI":"10.1016\/S1470-2045(21)00376-4"},{"key":"2023013016571672700_i2590-017X-6-1-31-b53","doi-asserted-by":"crossref","unstructured":"Murai\n              J,\n             Huang S-yN,\n\t\t\t\t\t\tDasBB,et al.\n          Trapping of PARP1 and PARP2 by clinical PARP inhibitors.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2012;\n\t\t\t\t\t72:\n\t\t\t\t\t5588\u2013\n\t\t\t\t\t5599.","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"2023013016571672700_i2590-017X-6-1-31-b54","doi-asserted-by":"crossref","unstructured":"Domchek\n              S,\n            \n            \n              Postel-Vinay\n              S,\n            \n            \n              Im\n              SA,\n            \n            et al.\n          \n          1191O Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Ann Oncol.\n          2019;\n\t\t\t\t\t30(suppl_5):v477.","DOI":"10.1093\/annonc\/mdz253.017"},{"key":"2023013016571672700_i2590-017X-6-1-31-b55","doi-asserted-by":"crossref","unstructured":"Golan\n              T,\n            \n            \n              Hammel\n              P,\n            \n            \n              Reni\n              M,\n            \n            et al.\n          \n          Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol.\n          2021;\n\t\t\t\t\t39(3_suppl):378.","DOI":"10.1200\/JCO.2021.39.3_suppl.378"},{"key":"2023013016571672700_i2590-017X-6-1-31-b56","doi-asserted-by":"crossref","unstructured":"Bendell\n              J,\n            \n            \n              O'Reilly\n              EM,\n            \n            \n              Middleton\n              MR,\n            \n            et al.\n          \n          Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t26:\n\t\t\t\t\t804\u2013\n\t\t\t\t\t811.","DOI":"10.1093\/annonc\/mdu581"},{"key":"2023013016571672700_i2590-017X-6-1-31-b57","doi-asserted-by":"crossref","unstructured":"Bang\n              YJ,\n            \n            \n              Xu\n              RH,\n            \n            \n              Chin\n              K,\n            \n            et al.\n          \n          Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t18:\n\t\t\t\t\t1637\u2013\n\t\t\t\t\t1651.","DOI":"10.1016\/S1470-2045(17)30682-4"},{"key":"2023013016571672700_i2590-017X-6-1-31-b58","doi-asserted-by":"crossref","unstructured":"Mo\n              M,\n            \n            \n              Yang\n              J,\n            \n            \n              Zhu\n              X,\n            \n            \n              Zhu\n              J.\n            \n          \n          Use of olaparib in patients with advanced gastric cancer.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t19:\n\t\t\t\t\te75.","DOI":"10.1016\/S1470-2045(18)30023-8"},{"key":"2023013016571672700_i2590-017X-6-1-31-b59","doi-asserted-by":"crossref","unstructured":"Lin\n              KK,\n            \n            \n              Harrell\n              MI,\n            \n            \n              Oza\n              AM,\n            \n            et al.\n          \n          BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2019;\n\t\t\t\t\t9:\n\t\t\t\t\t210\u2013\n\t\t\t\t\t219.","DOI":"10.1158\/2159-8290.CD-18-0715"},{"key":"2023013016571672700_i2590-017X-6-1-31-b60","doi-asserted-by":"crossref","unstructured":"Pettitt\n              SJ,\n            \n            \n              Krastev\n              DB,\n            \n            \n              Brandsma\n              I,\n            \n            et al.\n          \n          Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2018;\n\t\t\t\t\t9:\n\t\t\t\t\t1849.","DOI":"10.1038\/s41467-018-03917-2"},{"key":"2023013016571672700_i2590-017X-6-1-31-b61","doi-asserted-by":"crossref","unstructured":"Gogola\n              E,\n            \n            \n              Duarte\n              AA,\n            \n            \n              de Ruiter\n              JR,\n            \n            et al.\n          \n          Selective loss of PARG restores PARylation and\n\t\t\t\t\tCounteractsPARPInhibitor-Mediated Synthetic Lethality.\n\t\t\t\t\tCancer Cell.\n\t\t\t\t\t2018;\n\t\t\t\t\t33:\n\t\t\t\t\t1078\u2013\n\t\t\t\t\t1093.e12.","DOI":"10.1016\/j.ccell.2018.05.008"},{"key":"2023013016571672700_i2590-017X-6-1-31-b62","doi-asserted-by":"crossref","unstructured":"Nesic\n              K,\n            \n            \n              Kondrashova\n              O,\n            \n            \n              Hurley\n              RM,\n            \n            et al.\n          \n          Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2021;\n\t\t\t\t\t81:\n\t\t\t\t\t4709\u2013\n\t\t\t\t\t4722.","DOI":"10.1158\/0008-5472.CAN-21-0774"},{"key":"2023013016571672700_i2590-017X-6-1-31-b63","doi-asserted-by":"crossref","unstructured":"Kondrashova\n              O,\n            \n            \n              Topp\n              M,\n            \n            \n              Nesic\n              K,\n            \n            et al.\n          \n          Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2018;\n\t\t\t\t\t9:\n\t\t\t\t\t3970.","DOI":"10.1038\/s41467-018-05564-z"},{"key":"2023013016571672700_i2590-017X-6-1-31-b64","doi-asserted-by":"crossref","unstructured":"Collot\n              T,\n            \n            \n              Niogret\n              J,\n            \n            \n              Carnet\n              M,\n            \n            et al.\n          \n          PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: four case reports.\n\t\t\t\t\tMol Med Rep.\n\t\t\t\t\t2021;\n\t\t\t\t\t23:\n\t\t\t\t\t75.","DOI":"10.3892\/mmr.2020.11713"},{"key":"2023013016571672700_i2590-017X-6-1-31-b65","doi-asserted-by":"crossref","unstructured":"Mo\n              W,\n            \n            \n              Liu\n              Q,\n            \n            \n              Lin\n              CC,\n            \n            et al.\n          \n          mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2016;\n\t\t\t\t\t22:\n\t\t\t\t\t1699\u2013\n\t\t\t\t\t712.","DOI":"10.1158\/1078-0432.CCR-15-1772"},{"key":"2023013016571672700_i2590-017X-6-1-31-b66","doi-asserted-by":"crossref","unstructured":"Sun\n              C,\n            \n            \n              Fang\n              Y,\n            \n            \n              Yin\n              J,\n            \n            et al.\n          \n          Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med.\n          2017;\n\t\t\t\t\t9:eaal5148.","DOI":"10.1126\/scitranslmed.aal5148"},{"key":"2023013016571672700_i2590-017X-6-1-31-b67","doi-asserted-by":"crossref","unstructured":"Li\n              L,\n            \n            \n              Karanika\n              S,\n            \n            \n              Yang\n              G,\n            \n            et al.\n          \n          Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal.\n          2017;\n\t\t\t\t\t10:eaam7479.","DOI":"10.1126\/scisignal.aam7479"},{"key":"2023013016571672700_i2590-017X-6-1-31-b68","doi-asserted-by":"crossref","unstructured":"Kanakkanthara\n              A,\n            \n            \n              Hou\n              X,\n            \n            \n              Ekstrom\n              TL,\n            \n            et al.\n          \n          Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2022;\n\t\t\t\t\t82:\n\t\t\t\t\t307\u2013\n\t\t\t\t\t319.","DOI":"10.1158\/0008-5472.CAN-21-0732"},{"key":"2023013016571672700_i2590-017X-6-1-31-b69","doi-asserted-by":"crossref","unstructured":"Shiloh\n              Y,\n            \n            \n              Ziv\n              Y.\n            \n          \n          The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.\n\t\t\t\t\tNat Rev Mol Cell Biol.\n\t\t\t\t\t2013;\n\t\t\t\t\t14:\n\t\t\t\t\t197\u2013\n\t\t\t\t\t210.","DOI":"10.1038\/nrm3546"},{"key":"2023013016571672700_i2590-017X-6-1-31-b70","doi-asserted-by":"crossref","unstructured":"Ma\n              CX,\n            \n            \n              Ellis\n              MJ,\n            \n            \n              Petroni\n              GR,\n            \n            et al.\n          \n          A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.\n\t\t\t\t\tBreast Cancer Res Treat.\n\t\t\t\t\t2013;\n\t\t\t\t\t137:\n\t\t\t\t\t483\u2013\n\t\t\t\t\t492.","DOI":"10.1007\/s10549-012-2378-9"},{"key":"2023013016571672700_i2590-017X-6-1-31-b71","doi-asserted-by":"crossref","unstructured":"Sausville\n              E,\n            \n            \n              Lorusso\n              P,\n            \n            \n              Carducci\n              M,\n            \n            et al.\n          \n          Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.\n\t\t\t\t\tCancer Chemother Pharmacol.\n\t\t\t\t\t2014;\n\t\t\t\t\t73:\n\t\t\t\t\t539\u2013\n\t\t\t\t\t549.","DOI":"10.1007\/s00280-014-2380-5"},{"key":"2023013016571672700_i2590-017X-6-1-31-b72","doi-asserted-by":"crossref","unstructured":"Wehler\n              T,\n            \n            \n              Thomas\n              M,\n            \n            \n              Schumann\n              C,\n            \n            et al.\n          \n          A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.\n\t\t\t\t\tLung Cancer.\n\t\t\t\t\t2017;\n\t\t\t\t\t108:\n\t\t\t\t\t212\u2013\n\t\t\t\t\t216.","DOI":"10.1016\/j.lungcan.2017.03.001"},{"key":"2023013016571672700_i2590-017X-6-1-31-b73","doi-asserted-by":"crossref","unstructured":"Al-Ahmadie\n              H,\n            \n            \n              Iyer\n              G,\n            \n            \n              Hohl\n              M,\n            \n            et al.\n          \n          Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2014;\n\t\t\t\t\t4:\n\t\t\t\t\t1014\u2013\n\t\t\t\t\t1021.","DOI":"10.1158\/2159-8290.CD-14-0380"},{"key":"2023013016571672700_i2590-017X-6-1-31-b74","doi-asserted-by":"crossref","unstructured":"Yang\n              ES,\n            \n            \n              Deutsch\n              E,\n            \n            \n              Mehmet\n              A,\n            \n            et al.\n          \n          A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.\n\t\t\t\t\tRadiother Oncol.\n\t\t\t\t\t2021;\n\t\t\t\t\t157:\n\t\t\t\t\t203\u2013\n\t\t\t\t\t209.","DOI":"10.1016\/j.radonc.2021.01.032"},{"key":"2023013016571672700_i2590-017X-6-1-31-b75","doi-asserted-by":"crossref","unstructured":"Hong\n              DS,\n            \n            \n              Moore\n              K,\n            \n            \n              Patel\n              M,\n            \n            et al.\n          \n          Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2018;\n\t\t\t\t\t24:\n\t\t\t\t\t3263\u2013\n\t\t\t\t\t3272.","DOI":"10.1158\/1078-0432.CCR-17-3347"},{"key":"2023013016571672700_i2590-017X-6-1-31-b76","doi-asserted-by":"crossref","unstructured":"Esashi\n              F,\n            \n            \n              Christ\n              N,\n            \n            \n              Gannon\n              J,\n            \n            et al.\n          \n          CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.\n\t\t\t\t\tNature.\n\t\t\t\t\t2005;\n\t\t\t\t\t434:\n\t\t\t\t\t598\u2013\n\t\t\t\t\t604.","DOI":"10.1038\/nature03404"},{"key":"2023013016571672700_i2590-017X-6-1-31-b77","doi-asserted-by":"crossref","unstructured":"Geenen\n              JJJ,\n            \n            \n              Schellens\n              JHM.\n            \n          \n          Molecular pathways: targeting the protein kinase Wee1 in cancer.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t23:\n\t\t\t\t\t4540\u2013\n\t\t\t\t\t4544.","DOI":"10.1158\/1078-0432.CCR-17-0520"},{"key":"2023013016571672700_i2590-017X-6-1-31-b78","doi-asserted-by":"crossref","unstructured":"Bridges\n              KA,\n            \n            \n              Hirai\n              H,\n            \n            \n              Buser\n              CA,\n            \n            et al.\n          \n          MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2011;\n\t\t\t\t\t17:\n\t\t\t\t\t5638\u2013\n\t\t\t\t\t5648.","DOI":"10.1158\/1078-0432.CCR-11-0650"},{"key":"2023013016571672700_i2590-017X-6-1-31-b79","doi-asserted-by":"crossref","unstructured":"Aarts\n              M,\n            \n            \n              Sharpe\n              R,\n            \n            \n              Garcia-Murillas\n              I,\n            \n            et al.\n          \n          Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2012;\n\t\t\t\t\t2:\n\t\t\t\t\t524\u2013\n\t\t\t\t\t539.","DOI":"10.1158\/2159-8290.CD-11-0320"},{"key":"2023013016571672700_i2590-017X-6-1-31-b80","doi-asserted-by":"crossref","unstructured":"Chera\n              BS,\n            \n            \n              Sheth\n              SH,\n            \n            \n              Patel\n              SA,\n            \n            et al.\n          \n          Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.\n\t\t\t\t\tCancer.\n\t\t\t\t\t2021;\n\t\t\t\t\t127:\n\t\t\t\t\t4447\u2013\n\t\t\t\t\t4454.","DOI":"10.1002\/cncr.33789"},{"key":"2023013016571672700_i2590-017X-6-1-31-b81","doi-asserted-by":"crossref","unstructured":"Chen\n              DS,\n            \n            \n              Mellman\n              I.\n            \n          \n          Elements of cancer immunity and the cancer\u2013immune set point.\n\t\t\t\t\tNature.\n\t\t\t\t\t2017;\n\t\t\t\t\t541:\n\t\t\t\t\t321\u2013\n\t\t\t\t\t330.","DOI":"10.1038\/nature21349"},{"key":"2023013016571672700_i2590-017X-6-1-31-b82","doi-asserted-by":"crossref","unstructured":"Sharma\n              P,\n            \n            \n              Allison James\n              P.\n            \n          \n          Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.\n\t\t\t\t\tCell.\n\t\t\t\t\t2015;\n\t\t\t\t\t161:\n\t\t\t\t\t205\u2013\n\t\t\t\t\t214.","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"2023013016571672700_i2590-017X-6-1-31-b83","doi-asserted-by":"crossref","unstructured":"Ricciuti\n              B,\n            \n            \n              Recondo\n              G,\n            \n            \n              Spurr\n              LF,\n            \n            et al.\n          \n          Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\t4135\u2013\n\t\t\t\t\t4142.","DOI":"10.1158\/1078-0432.CCR-19-3529"},{"key":"2023013016571672700_i2590-017X-6-1-31-b84","doi-asserted-by":"crossref","unstructured":"Teo\n              MY,\n            \n            \n              Seier\n              K,\n            \n            \n              Ostrovnaya\n              I,\n            \n            et al.\n          \n          Alterations in DNA damage response and repair genes as potential marker of clinical benefit From PD-1\/PD-L1 blockade in advanced urothelial cancers.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t36:\n\t\t\t\t\t1685\u2013\n\t\t\t\t\t1694.","DOI":"10.1200\/JCO.2017.75.7740"},{"key":"2023013016571672700_i2590-017X-6-1-31-b85","doi-asserted-by":"crossref","unstructured":"Le\n              DT,\n            \n            \n              Durham\n              JN,\n            \n            \n              Smith\n              KN,\n            \n            et al.\n          \n          Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.\n\t\t\t\t\tScience.\n\t\t\t\t\t2017;\n\t\t\t\t\t357:\n\t\t\t\t\t409\u2013\n\t\t\t\t\t413.","DOI":"10.1126\/science.aan6733"},{"key":"2023013016571672700_i2590-017X-6-1-31-b86","doi-asserted-by":"crossref","unstructured":"McGranahan\n              N,\n            \n            \n              Furness\n              AJS,\n            \n            \n              Rosenthal\n              R,\n            \n            et al.\n          \n          Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.\n\t\t\t\t\tScience.\n\t\t\t\t\t2016;\n\t\t\t\t\t351:\n\t\t\t\t\t1463\u2013\n\t\t\t\t\t1469.","DOI":"10.1126\/science.aaf1490"},{"key":"2023013016571672700_i2590-017X-6-1-31-b87","doi-asserted-by":"crossref","unstructured":"Wen\n              WX,\n            \n            \n              Leong\n              C-O.\n            \n          \n          Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1\/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2019;\n\t\t\t\t\t14:\n\t\t\t\t\te0215381.","DOI":"10.1371\/journal.pone.0215381"},{"key":"2023013016571672700_i2590-017X-6-1-31-b88","doi-asserted-by":"crossref","unstructured":"Jiao\n              S,\n            \n            \n              Xia\n              W,\n            \n            \n              Yamaguchi\n              H,\n            \n            et al.\n          \n          PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t23:\n\t\t\t\t\t3711\u2013\n\t\t\t\t\t3720.","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"2023013016571672700_i2590-017X-6-1-31-b89","doi-asserted-by":"crossref","unstructured":"Reislander\n              T,\n            \n            \n              Groelly\n              FJ,\n            \n            \n              Tarsounas\n              M.\n            \n          \n          DNA damage and cancer immunotherapy: a STING in the tale.\n\t\t\t\t\tMol Cell.\n\t\t\t\t\t2020;\n\t\t\t\t\t80:\n\t\t\t\t\t21\u2013\n\t\t\t\t\t28.","DOI":"10.1016\/j.molcel.2020.07.026"},{"key":"2023013016571672700_i2590-017X-6-1-31-b90","doi-asserted-by":"crossref","unstructured":"Sun\n              W,\n            \n            \n              Zhang\n              Q,\n            \n            \n              Wang\n              R,\n            \n            et al.\n          \n          Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications.\n\t\t\t\t\tFront Oncol.\n\t\t\t\t\t2021;\n\t\t\t\t\t11:\n\t\t\t\t\t648687.","DOI":"10.3389\/fonc.2021.648687"},{"key":"2023013016571672700_i2590-017X-6-1-31-b91","doi-asserted-by":"crossref","unstructured":"Brown\n              JS,\n            \n            \n              O'Carrigan\n              B,\n            \n            \n              Jackson\n              SP,\n            \n            \n              Yap\n              TA.\n            \n          \n          Targeting DNA repair in cancer: beyond PARP inhibitors.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2017;\n\t\t\t\t\t7:\n\t\t\t\t\t20\u2013\n\t\t\t\t\t37.","DOI":"10.1158\/2159-8290.CD-16-0860"},{"key":"2023013016571672700_i2590-017X-6-1-31-b92","doi-asserted-by":"crossref","unstructured":"Tu\n              X,\n            \n            \n              Qin\n              B,\n            \n            \n              Zhang\n              Y,\n            \n            et al.\n          \n          PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy.\n\t\t\t\t\tMol Cell.\n\t\t\t\t\t2019;\n\t\t\t\t\t74:\n\t\t\t\t\t1215\u2013\n\t\t\t\t\t1226.e4.","DOI":"10.1016\/j.molcel.2019.04.005"},{"key":"2023013016571672700_i2590-017X-6-1-31-b93","doi-asserted-by":"crossref","unstructured":"Escors\n              D,\n            \n            \n              Gato-Canas\n              M,\n            \n            \n              Zuazo\n              M,\n            \n            et al.\n          \n          The intracellular signalosome of PD-L1 in cancer cells.\n\t\t\t\t\tSignal Transduct Target Ther.\n\t\t\t\t\t2018;\n\t\t\t\t\t3:\n\t\t\t\t\t26.","DOI":"10.1038\/s41392-018-0022-9"},{"key":"2023013016571672700_i2590-017X-6-1-31-b94","doi-asserted-by":"crossref","unstructured":"Chang\n              CH,\n            \n            \n              Qiu\n              J,\n            \n            \n              O'Sullivan\n              D,\n            \n            et al.\n          \n          Metabolic competition in the tumor microenvironment is a driver of cancer progression.\n\t\t\t\t\tCell.\n\t\t\t\t\t2015;\n\t\t\t\t\t162:\n\t\t\t\t\t1229\u2013\n\t\t\t\t\t1241.","DOI":"10.1016\/j.cell.2015.08.016"},{"key":"2023013016571672700_i2590-017X-6-1-31-b95","doi-asserted-by":"crossref","unstructured":"Clark\n              CA,\n            \n            \n              Gupta\n              HB,\n            \n            \n              Sareddy\n              G,\n            \n            et al.\n          \n          Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2016;\n\t\t\t\t\t76:\n\t\t\t\t\t6964\u2013\n\t\t\t\t\t6974.","DOI":"10.1158\/0008-5472.CAN-16-0258"},{"key":"2023013016571672700_i2590-017X-6-1-31-b96","doi-asserted-by":"crossref","unstructured":"Gupta\n              HB,\n            \n            \n              Clark\n              CA,\n            \n            \n              Yuan\n              B,\n            \n            et al.\n          \n          Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.\n\t\t\t\t\tSignal Transduct Target Ther.\n\t\t\t\t\t2016;\n\t\t\t\t\t1:\n\t\t\t\t\t16030.","DOI":"10.1038\/sigtrans.2016.30"},{"key":"2023013016571672700_i2590-017X-6-1-31-b97","doi-asserted-by":"crossref","unstructured":"Clark\n              CA,\n            \n            \n              Yang\n              ES.\n            \n          \n          Harnessing DNA repair defects to augment immune-based therapies in triple-negative breast cancer.\n\t\t\t\t\tFront Oncol.\n\t\t\t\t\t2021;\n\t\t\t\t\t11:\n\t\t\t\t\t703802.","DOI":"10.3389\/fonc.2021.703802"},{"key":"2023013016571672700_i2590-017X-6-1-31-b98","doi-asserted-by":"crossref","unstructured":"Vikas\n              P,\n            \n            \n              Borcherding\n              N,\n            \n            \n              Chennamadhavuni\n              A,\n            \n            \n              Garje\n              R.\n            \n          \n          Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors.\n\t\t\t\t\tFront Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t10:\n\t\t\t\t\t570.","DOI":"10.3389\/fonc.2020.00570"},{"key":"2023013016571672700_i2590-017X-6-1-31-b99","doi-asserted-by":"crossref","unstructured":"Higuchi\n              T,\n            \n            \n              Flies\n              DB,\n            \n            \n              Marjon\n              NA,\n            \n            et al.\n          \n          CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer.\n\t\t\t\t\tCancer Immunol Res.\n\t\t\t\t\t2015;\n\t\t\t\t\t3:\n\t\t\t\t\t1257\u2013\n\t\t\t\t\t1268.","DOI":"10.1158\/2326-6066.CIR-15-0044"},{"key":"2023013016571672700_i2590-017X-6-1-31-b100","doi-asserted-by":"crossref","unstructured":"Vinayak\n              S,\n            \n            \n              Tolaney\n              SM,\n            \n            \n              Schwartzberg\n              L,\n            \n            et al.\n          \n          Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.\n\t\t\t\t\tJAMA Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t5:\n\t\t\t\t\t1132\u2013\n\t\t\t\t\t1140.","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"2023013016571672700_i2590-017X-6-1-31-b101","doi-asserted-by":"crossref","unstructured":"Konstantinopoulos\n              PA,\n            \n            \n              Waggoner\n              S,\n            \n            \n              Vidal\n              GA,\n            \n            et al.\n          \n          Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma.\n\t\t\t\t\tJAMA Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t5:\n\t\t\t\t\t1141\u2013\n\t\t\t\t\t1149.","DOI":"10.1001\/jamaoncol.2019.1048"},{"key":"2023013016571672700_i2590-017X-6-1-31-b102","doi-asserted-by":"crossref","unstructured":"Ottini\n              A,\n            \n            \n              Sepe\n              P,\n            \n            \n              Beninato\n              T,\n            \n            et al.\n          \n          Biomarker-driven immunotherapy for precision medicine in prostate cancer.\n\t\t\t\t\tPer Med.\n\t\t\t\t\t2022;\n\t\t\t\t\t19:\n\t\t\t\t\t51\u2013\n\t\t\t\t\t66.","DOI":"10.2217\/pme-2021-0079"},{"key":"2023013016571672700_i2590-017X-6-1-31-b103","doi-asserted-by":"crossref","unstructured":"Spigel\n              DR,\n            \n            \n              Faivre-Finn\n              C,\n            \n            \n              Gray\n              JE,\n            \n            et al.\n          \n          Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2022;\n\t\t\t\t\t40:\n\t\t\t\t\t1301\u2013\n\t\t\t\t\t1311.","DOI":"10.1200\/JCO.21.01308"},{"key":"2023013016571672700_i2590-017X-6-1-31-b104","doi-asserted-by":"crossref","unstructured":"Thomas\n              A,\n            \n            \n              Vilimas\n              R,\n            \n            \n              Trindade\n              C,\n            \n            et al.\n          \n          Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a Phase II study.\n\t\t\t\t\tJ Thorac Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t14:\n\t\t\t\t\t1447\u2013\n\t\t\t\t\t1457.","DOI":"10.1016\/j.jtho.2019.04.026"},{"key":"2023013016571672700_i2590-017X-6-1-31-b105","unstructured":"Sun\n              LL,\n            \n            \n              Yang\n              RY,\n            \n            \n              Li\n              CW,\n            \n            et al.\n          \n          Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.\n\t\t\t\t\tAm J Cancer Res.\n\t\t\t\t\t2018;\n\t\t\t\t\t8:\n\t\t\t\t\t1307\u2013\n\t\t\t\t\t1316."},{"key":"2023013016571672700_i2590-017X-6-1-31-b106","doi-asserted-by":"crossref","unstructured":"Kim\n              R,\n            \n            \n              Kwon\n              M,\n            \n            \n              An\n              M,\n            \n            et al.\n          \n          Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2022;\n\t\t\t\t\t33:\n\t\t\t\t\t193\u2013\n\t\t\t\t\t203.","DOI":"10.1016\/j.annonc.2021.10.009"},{"key":"2023013016571672700_i2590-017X-6-1-31-b107","doi-asserted-by":"crossref","unstructured":"Patel\n              MR,\n            \n            \n              Falchook\n              GS,\n            \n            \n              Wang\n              JS-Z,\n            \n            et al.\n          \n          Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. J Clin Oncol.\n          2019;\n\t\t\t\t\t37(15_suppl):2562\u20132562.","DOI":"10.1200\/JCO.2019.37.15_suppl.2562"},{"key":"2023013016571672700_i2590-017X-6-1-31-b108","doi-asserted-by":"crossref","unstructured":"Powles\n              T,\n            \n            \n              Carroll\n              D,\n            \n            \n              Chowdhury\n              S,\n            \n            et al.\n          \n          An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.\n\t\t\t\t\tNat Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t27:\n\t\t\t\t\t793\u2013\n\t\t\t\t\t801.","DOI":"10.1038\/s41591-021-01317-6"},{"key":"2023013016571672700_i2590-017X-6-1-31-b109","doi-asserted-by":"crossref","unstructured":"Deng\n              J,\n            \n            \n              Wang\n              ES,\n            \n            \n              Jenkins\n              RW,\n            \n            et al.\n          \n          CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2018;\n\t\t\t\t\t8:\n\t\t\t\t\t216\u2013\n\t\t\t\t\t233.","DOI":"10.1158\/2159-8290.CD-17-0915"},{"key":"2023013016571672700_i2590-017X-6-1-31-b110","doi-asserted-by":"crossref","unstructured":"Teo\n              ZL,\n            \n            \n              Versaci\n              S,\n            \n            \n              Dushyanthen\n              S,\n            \n            et al.\n          \n          Combined CDK4\/6 and PI3Kalpha inhibition is synergistic and immunogenic in triple-negative breast cancer.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t77:\n\t\t\t\t\t6340\u2013\n\t\t\t\t\t6352.","DOI":"10.1158\/0008-5472.CAN-17-2210"},{"key":"2023013016571672700_i2590-017X-6-1-31-b111","doi-asserted-by":"crossref","unstructured":"Zhang\n              Q,\n            \n            \n              Green\n              MD,\n            \n            \n              Lang\n              X,\n            \n            et al.\n          \n          Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2019;\n\t\t\t\t\t79:\n\t\t\t\t\t3940\u2013\n\t\t\t\t\t3951.","DOI":"10.1158\/0008-5472.CAN-19-0761"},{"key":"2023013016571672700_i2590-017X-6-1-31-b112","doi-asserted-by":"crossref","unstructured":"Wang\n              L,\n            \n            \n              Yang\n              L,\n            \n            \n              Wang\n              C,\n            \n            et al.\n          \n          Inhibition of the ATM\/Chk2 axis promotes cGAS\/STING signaling in ARID1A-deficient tumors.\n\t\t\t\t\tJ Clin Invest.\n\t\t\t\t\t2020;\n\t\t\t\t\t130:\n\t\t\t\t\t5951\u2013\n\t\t\t\t\t5966.","DOI":"10.1172\/JCI130445"},{"key":"2023013016571672700_i2590-017X-6-1-31-b113","doi-asserted-by":"crossref","unstructured":"Burleigh\n              K,\n            \n            \n              Maltbaek\n              JH,\n            \n            \n              Cambier\n              S,\n            \n            et al.\n          \n          Human DNA-PK activates a STING-independent DNA sensing pathway. Sci Immunol.\n          2020;\n\t\t\t\t\t5:eaba4219.","DOI":"10.1126\/sciimmunol.aba4219"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/1\/31\/3184573\/i2590-017x-6-1-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/1\/31\/3184573\/i2590-017x-6-1-31.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:36Z","timestamp":1765475316000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/6\/1\/article-p31.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,2]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-22-15","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}